{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:39:18Z","timestamp":1788406758881,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of canakinumab 4\u00a0mg\/kg every 4\u00a0weeks administered subcutaneously in Japanese adult-onset Still\u2019s disease patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fourteen participants were included in this open-label, single-arm, active-treatment study. The primary endpoint was the adapted ACR30 response, with a predefined 95% CI lower limit requirement of 40% at Week 8. Secondary endpoints included glucocorticoid tapering from Weeks 8 to 28; adapted ACR30\/50\/70\/90\/100 responses over time; and the systemic feature score over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary endpoint was not met [6\/11 patients (54.5%); 95% CI: 20.6\u201388.5; one-sided P\u00a0=\u20090.249]. From Weeks 8 to 28, 6\/11 patients (54.5%) successfully tapered oral glucocorticoids. At Week 28, among the 11 patients assessed, 70% achieved adapted ACR30 and adapted ACR50, 60% achieved adapted ACR70 and adapted ACR90, and 40% achieved adapted ACR100. At Week 28, the mean (SD) change from baseline in the systemic feature score was \u22124.3 (2.06). All 14 patients had at least one treatment-emergent adverse event. Six participants (42.9%) had serious adverse events. Three patients had serious infections; all were considered treatment-related and all recovered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although the primary endpoint was not met, the Week 28 analysis showed that canakinumab treatment led to improvements in various efficacy outcome measures in Japanese patients with adult-onset Still\u2019s disease, with no unexpected safety signals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag026","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:20:14Z","timestamp":1774268414000},"page":"809-816","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of canakinumab in patients with adult-onset Still\u2019s disease: Results from an open-label phase III study in Japan"],"prefix":"10.1093","volume":"36","author":[{"given":"Tatsuya","family":"Atsumi","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-661X","authenticated-orcid":false,"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University , Yokohama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kanazawa University , Kanazawa ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Mimura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Saitama Medical University , Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kawaai","sequence":"additional","affiliation":[{"name":"Immuno-Rheumatology Center, St. Luke's International Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Seko","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Hongo","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmath","family":"Patekar","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026083106415714000_ref1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-024-01993-x","article-title":"Adult-onset Still's disease (AOSD): advances in understanding pathophysiology, genetics and emerging treatment options","volume":"84","author":"Bindoli","year":"2024","journal-title":"Drugs"},{"key":"2026083106415714000_ref2","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/rheumatology\/kead461","article-title":"Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts","volume":"63","author":"Leavis","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026083106415714000_ref3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/mr\/roaf009","article-title":"Blood monocyte fraction and computed tomography attenuation value of bone marrow in fever of unknown origin: a retrospective analysis for differentiating adult-onset Still\u2019s disease and intravascular large B-cell lymphoma","volume":"35","author":"Oda","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026083106415714000_ref4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/25785826.2024.2411094","article-title":"Identification of novel cytokine to judge the diagnosis and clinical phenotype of adult-onset Still's disease","volume":"48","author":"Yoshida","year":"2025","journal-title":"Immunol Med"},{"key":"2026083106415714000_ref5","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s40265-018-0956-9","article-title":"Adult-onset Still's disease: molecular pathophysiology and therapeutic advances","volume":"78","author":"Sfriso","year":"2018","journal-title":"Drugs."},{"key":"2026083106415714000_ref6","doi-asserted-by":"crossref","first-page":"8998358","DOI":"10.1155\/2021\/8998358","article-title":"An update on the pathogenic role of macrophages in adult-onset Still's disease and its implication in clinical manifestations and novel therapeutics","volume":"2021","author":"Chen","year":"2021","journal-title":"J Immunol Res"},{"key":"2026083106415714000_ref7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026083106415714000_ref8","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1136\/ard-2024-225851","article-title":"EULAR\/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease","volume":"83","author":"Fautrel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026083106415714000_ref9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/25785826.2024.2388346","article-title":"Successful maintenance therapy with tocilizumab for severe acute liver failure associated with adult-onset still's disease","volume":"48","author":"Suzuki","year":"2025","journal-title":"Immunol Med"},{"key":"2026083106415714000_ref10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/14397595.2014.974881","article-title":"Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan","volume":"25","author":"Asanuma","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2026083106415714000_ref11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/14397595.2018.1465633","article-title":"Evidence-based clinical practice guideline for adult Still's disease","volume":"28","author":"Mimura","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2026083106415714000_ref12","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026083106415714000_ref13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/1744666X.2019.1707664","article-title":"Canakinumab for the treatment of adult-onset Still's disease","volume":"16","author":"Sfriso","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2026083106415714000_ref14","article-title":"EU summary of product characteristics - Ilaris, INN-canakinumab"},{"key":"2026083106415714000_ref15","article-title":"ILARIS\u00ae (canakinumab) injection, for subcutaneous use initial U.S. approval: 2009 2020"},{"key":"2026083106415714000_ref16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026083106415714000_ref17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American College of Rheumatology\/paediatric rheumatology international trials organisation collaborative initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026083106415714000_ref18","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag026\/67499488\/roag026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/809\/67499488\/roag026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/809\/67499488\/roag026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:42:03Z","timestamp":1788172923000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/5\/809\/8539697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,24]]},"published-print":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag026","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,24]]}}}